Integrative Medicine in Nephrology and Andrology最新文献_第4页

Clinical Characteristics and Chinese Medicine Therapy of Chronic Kidney Disease Combined with Cardiovascular Disease 慢性肾病合并心血管病的临床特点及中医治疗

Integrative Medicine in Nephrology and Andrology Pub Date : 2023-03-01 DOI: 10.1097/imna-d-22-00023

T. Zhu, Yating Du, Mingyang Xuan, Chuan Guo, Xia Rao

引用次数: 0

Traditional Chinese medicine regulates inflammatory factors in chronic prostatitis/chronic pelvic pain syndrome: A review 中药调节慢性前列腺炎/慢性盆腔疼痛综合征炎症因子的研究进展

Integrative Medicine in Nephrology and Andrology Pub Date : 2023-03-01 DOI: 10.1097/imna-d-22-00001

Hao Wang, Ming Zhao, Ji-wei Zhang, B. Yan, Q. Gao, Jun Guo

引用次数: 2

Mesenchymal Stem Cells in the Treatment of Acute Kidney Injury (AKI), Chronic Kidney Disease (CKD) and the AKI-to-CKD Transition 间充质干细胞治疗急性肾损伤(AKI)、慢性肾脏疾病(CKD)和从AKI到CKD的转变

Integrative Medicine in Nephrology and Andrology Pub Date : 2023-03-01 DOI: 10.1097/imna-d-22-00014

Charles Stuart Allinson, C. Pollock, Xinming Chen

引用次数: 1

New Insights into Traditional Chinese Medicine in Treatment of Diabetic Nephropathy 中医药治疗糖尿病肾病的新认识

Integrative Medicine in Nephrology and Andrology Pub Date : 2023-03-01 DOI: 10.1097/imna-d-22-00026

J. Chung, H. Lan, P. Tang

引用次数: 0

An Analysis on the Clinical Features of Maintenance Hemodialysis Patients with Coronavirus Disease 2019: A Single Center Study 2019冠状病毒病维持性血液透析患者临床特征分析:单中心研究

Integrative Medicine in Nephrology and Andrology Pub Date : 2022-06-28 DOI: 10.4103/imna.imna_6_22

Li Cheng, Y. Min, Can Tu, D. Mao, Yuan-Zhi Yang, Yuting Song, Sheng Wan, Yanqiong Ding, Fei Xiong

{"title":"An Analysis on the Clinical Features of Maintenance Hemodialysis Patients with Coronavirus Disease 2019: A Single Center Study","authors":"Li Cheng, Y. Min, Can Tu, D. Mao, Yuan-Zhi Yang, Yuting Song, Sheng Wan, Yanqiong Ding, Fei Xiong","doi":"10.4103/imna.imna_6_22","DOIUrl":"https://doi.org/10.4103/imna.imna_6_22","url":null,"abstract":"Background and Objectives: Patients on maintenance hemodialysis (MHD) are at high risk for coronavirus disease 2019 (COVID-19). However, patients undergoing MHD who are infected with COVID-19 are not fully studied. The objective of this study is to describe the characteristics of patients with COVID-19 undergoing MHD and provide a basis for the recognition and prevention of COVID-19 infection. Materials and Methods: Patients undergoing MHD were assigned into the normal group (537 cases), diagnosed group (66 cases), and suspected group (24 cases). General data, clinical symptoms, hemodialysis indicators, and laboratory indicators were collected and compared. Results: A total of 627 patients undergoing MHD were evaluated. The prevalence of COVID-19 was 10.53% (66/627), mortality was 18.18% (12/66), and death rate was 1.91% (12/627). In addition, 26% of patients were asymptomatic. Cough was the most common symptom (36%), followed by fatigue (16%), dyspnea (16%), and fever (13%). Ultrafiltration volume, ultrafiltration rate, and the duration of weekly dialysis in the diagnosed group were significantly lower than those in the other two groups. Moreover, neutrophil ratio and neutrophil, monocyte, and total carbon dioxide levels in the diagnosed group were significantly higher than those in the normal group, and the lymphocyte ratio was considerably lower than in the normal group. Sixty-five of the suspected and diagnosed patients had positive pulmonary CT findings. Conclusion: Compared with the general population, patients on hemodialysis have a significantly higher risk of contracting COVID-19 and postinfection mortality. Moreover, most patients undergoing hemodialysis have no obvious clinical symptoms after infection with COVID-19 but only have pulmonary changes which make it particularly important to screen and manage patients undergoing hemodialysis on outpatient basis.","PeriodicalId":349243,"journal":{"name":"Integrative Medicine in Nephrology and Andrology","volume":"13 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-06-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"115540431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Therapeutic Effect of Tocilizumab on Inhibiting Cytokine Release Syndrome in Severe Coronavirus Disease 2019 Patients 托珠单抗抑制2019年冠状病毒重症患者细胞因子释放综合征的疗效

Integrative Medicine in Nephrology and Andrology Pub Date : 2022-05-25 DOI: 10.4103/imna.imna_5_22

Leng Xu, Xin Liu, Yangwei Zhou, Aihua Liu, Xiaomao Xu, Xiaoxia Wang, Xue-lian Zhong, Yu Qiao, L. Wen, H. Xi, Y. Mao

{"title":"Therapeutic Effect of Tocilizumab on Inhibiting Cytokine Release Syndrome in Severe Coronavirus Disease 2019 Patients","authors":"Leng Xu, Xin Liu, Yangwei Zhou, Aihua Liu, Xiaomao Xu, Xiaoxia Wang, Xue-lian Zhong, Yu Qiao, L. Wen, H. Xi, Y. Mao","doi":"10.4103/imna.imna_5_22","DOIUrl":"https://doi.org/10.4103/imna.imna_5_22","url":null,"abstract":"Background and Objectives: Older adults are more susceptible to coronavirus disease 2019 (COVID-19). Interleukin-6 (IL-6) is an important cytokine in the cytokine release syndrome (CRS), and tocilizumab blocks the IL-6 receptor. The objective is to analyze the effect of tocilizumab on CRS in older patients with severe COVID-19. Materials and Methods: Between February 10 and March 21, 2020, a total of 19 patients aged ≥60 years with severe or critical COVID-19 met the study inclusion criteria at the Tongji Hospital in Wuhan City, Hubei Province, China. The patients were divided into two groups: the tocilizumab group, with IL-6 levels, which exceeded the upper limit of normal by >10-fold and non-tocilizumab group. Results: Patients in the tocilizumab group were older (73.20 ± 4.44 vs. 66.21 ± 5.06 years, P = 0.014), had lower lymphocyte counts (0.71 ± 0.18 vs. 1.18 ± 0.59 × 109/L, P = 0.016), and higher high-sensitivity C-reactive protein (hsCRP) levels (94.04 ± 57.24 vs. 51.65 ± 45.37 mg/L, P = 0.035). Increases in ferritin (FER) and hsCRP levels in patients in the tocilizumab group were marked. Except for one patient who died, IL-6, FER, hsCRP levels, and the neutrophil/lymphocyte ratio in the remaining four patients decreased following treatment with tocilizumab. Tocilizumab did not cause any serious adverse reactions. There were no differences in mortality, days until lung computerized tomography improvement, or renal function between the two groups. The total mortality rate was 10.53%. Conclusions: Our results support the therapeutic efficacy and safety of tocilizumab in older patients with severe COVID-19.","PeriodicalId":349243,"journal":{"name":"Integrative Medicine in Nephrology and Andrology","volume":"66 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-05-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"114788534","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Interpretation of the Expert Consensus on the Traditional Chinese Medicine Prevention and Treatment of Coronavirus Disease 2019 Omicron Variant Infections 《2019冠状病毒病组粒变异感染中医防治专家共识》解读

Integrative Medicine in Nephrology and Andrology Pub Date : 2022-01-01 DOI: 10.4103/2773-0387.360626

B. Fang, Xinhui Wang, Shaobai Wang, Li Kong, Y. Ye, Huagang Liu, Wensheng Qi, Wanyan Liu, Xucheng Li, Guiwei Li, Xiaorong Chen, Dechao Zhang, Hong-xia Su, Zhixu Yang, Jinlu Zhang, Wen Zhang, Shuang Zhou, Ruanjin Zhao, Yuxia Mo, Qun Liang, Wei Huang, Changhong Zhou

引用次数: 0

Role of TGF-β Signaling in Coronavirus Disease 2019 TGF-β信号在2019冠状病毒病中的作用

Integrative Medicine in Nephrology and Andrology Pub Date : 2022-01-01 DOI: 10.4103/2773-0387.348713

Junzhe Chen, Wenjing Wu, Wenbiao Wang, Ying Tang, H. Lan

引用次数: 0

Uric Acid: A Friend in the Past, a Foe in the Present 尿酸:过去是朋友，现在是敌人

Integrative Medicine in Nephrology and Andrology Pub Date : 2022-01-01 DOI: 10.4103/2773-0387.348714

A. Ejaz, J. Antenor, Vijay A G Kumar, Carlos A Roncal, Gabriela E Garcia, Ana Andrés-Hernando, M. Lanaspa, R. J. Johnson

引用次数: 1

Macrophage-myofibroblast Transition in Kidney Disease 肾脏疾病中的巨噬细胞-肌成纤维细胞转化

Integrative Medicine in Nephrology and Andrology Pub Date : 2022-01-01 DOI: 10.4103/2773-0387.358225

H. Lan

引用次数: 0